Skip to main content
Fig. 2 | BMC Psychiatry

Fig. 2

From: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study

Fig. 2

Change from baseline in ADHD-RS-IV total scores. Data are the mean change from baseline (i.e., the start of the previous double-blind trial [DBT]) for patients who transitioned from the placebo arm and guanfacine extended-release (GXR) arm and the mean change from week 0 of the long-term treatment study for new patients. Error bars denote standard deviations. ADHD-RS-IV: Attention-Deficit/Hyperactivity Disorder Rating Scale IV with Adult Prompts

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us